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Abstract
Introduction: Amyloid	 transthyretin	amyloidosis	 (ATTR)	 is	 a	progressive	and	often	
fatal	 disease	 caused	 by	 the	 buildup	 of	 mutated	 (hereditary	 ATTR	 [hATTR];	 also	
known	as	ATTR	variant	[ATTRv])	or	normal	transthyretin	(wild‐type	ATTR)	through‐
out	the	body.	Two	new	therapies—inotersen,	an	antisense	oligonucleotide	therapy,	
and	patisiran,	 an	RNA	 interference	 therapy—received	marketing	authorization	and	
represent	a	significant	advance	in	the	treatment	of	amyloidosis.	Herein,	we	describe	
the	clinical	presentation	of	ATTR,	commonly	used	procedures	 in	 its	diagnosis,	and	
current	treatment	landscape	for	ATTR,	with	a	focus	on	hATTR.
Methods: A	PubMed	search	from	2008	to	September	2018	was	conducted	to	review	
the	literature	on	ATTR.
Results: Until	recently,	there	have	been	few	treatment	options	for	polyneuropathy	
of	 hATTR.	 Inotersen	 and	 patisiran	 substantially	 reduce	 the	 amyloidogenic	 precur‐
sor	protein	transthyretin	and	have	demonstrated	efficacy	in	patients	with	early‐	and	
late‐stage	disease	and	in	slowing	or	improving	neuropathy	progression.	In	contrast,	
established	 therapies,	 such	as	 liver	 transplantation,	 typically	 reserved	 for	patients	
with	early‐stage	disease,	 and	 tafamidis,	 indicated	 for	 the	 treatment	of	 early‐stage	
disease	 in	Europe,	or	diflunisal,	a	nonsteroidal	anti‐inflammatory	drug	 that	 is	used	
off‐label,	are	associated	with	side	effects	and/or	unclear	efficacy	in	certain	patient	
populations.	Thus,	inotersen	and	patisiran	are	positioned	to	be	the	preferred	thera‐
peutic modalities.
Conclusions: Important	differences	between	inotersen	and	patisiran,	 including	for‐
mulation,	dosing,	 requirements	 for	premedications,	 and	 safety	monitoring,	 require	
an understanding and knowledge of each treatment for informed decision making.
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1  | INTRODUC TION
Amyloid	 transthyretin	 (TTR)	 amyloidosis	 (ATTR	 amyloidosis)	 is	 a	
rare,	progressive,	 and	 fatal	disease	caused	by	 the	buildup	of	amy‐
loid	fibrils	 in	organs	and	tissues	 (Connors	et	al.,	2016;	Koike	et	al.,	
2016;	Koike,	Yasuda,	et	al.,	2018).	 It	can	be	caused	by	the	buildup	
of	mutated	TTR,	 referred	 to	as	hereditary	ATTR	 (hATTR)	or	ATTR	
variant	(ATTRv),	or	by	the	buildup	of	normal	TTR,	referred	to	as	wild‐
type	ATTR	(wtATTR)	(Connors	et	al.,	2016;	Koike	et	al.,	2016;	Koike,	
Yasuda,	et	al.,	2018).	hATTR	is	transmitted	in	an	autosomal	dominant	
manner,	and	more	than	130	TTR gene mutations have been identi‐
fied	 thus	 far	 (Rowczenio	&	Wechalekar,	2018).	The	mechanism	by	
which	wild‐type	TTR becomes amyloidogenic is poorly understood. 
Until	 recently,	 therapeutic	 options	 have	 been	 limited	 for	 patients	
with	 hATTR.	 This	 review	 describes	 the	 clinical	 presentation	 and	
commonly used diagnostic procedures and provides an overview of 
the	current	treatment	landscape	for	ATTR,	with	a	focus	on	hATTR.
2  | METHODS
A	PubMed	search	from	2008	to	September	2018,	with	the	search	
terms	 “amyloid,”	 “amyloidosis,”	 “familial	 amyloid	 cardiomyopa‐
thy,”	 “familial	 amyloid	 polyneuropathy,”	 “inotersen,”	 “patisiran,”	
“tafamidis,”	 “diflunisal,”	 “liver	 transplant,”	 “doxycycline,”	 “AG10,”	
“PRX004,”	 “anti‐SAP,”	 “TTRsc02,”	 “epigallo‐catechin‐3‐gallate,”	
“SOM0226,”	 “tolcapone,”	 “NI‐301,”	 “RT24,”	 “NPT088,”	 “NPT289,”	
“LUNAR‐TTR,”	 “PTI‐110,”	 and	 “tauroursodeoxycholic	 acid,”	 limited	
to	 English‐only	 publications,	was	 conducted.	 Reference	 lists	were	
also reviewed to identify key publications.
3  | DISCUSSION/OBSERVATION
3.1 | Clinical presentation
Hereditary	ATTR	manifests	as	sensorimotor	neuropathy,	autonomic	
neuropathy,	 cardiomyopathy,	 and	 nephropathy,	 whereas	 wtATTR	
mainly	affects	the	heart,	especially	 in	men	˃60	years	old	 (Table	1)	
(Carr	et	al.,	2016;	Conceicao	et	al.,	2016;	Connors	et	al.,	2016;	Maurer	
et	al.,	2016).	Of	note,	manifestations	consistent	with	peripheral	and	
autonomic neuropathy involvement have been observed in patients 
with	wtATTR	 (Connors	et	al.,	2016;	Maurer	et	al.,	2016).	A	classic	
feature	of	hATTR	is	length‐dependent	peripheral	sensorimotor	neu‐
ropathy	 (Cappellari	et	al.,	2011;	Carr	et	al.,	2016).	Symptoms	typi‐
cally	progress	in	a	distal	to	proximal	direction	with	feet	affected	first	
followed	by	upper	 limb	 involvement	 (Carr	et	al.,	2016).	As	the	dis‐
ease	progresses,	patients	experience	 increasing	 lower	 limb	muscle	
weakness,	walking	difficulty,	imbalance,	and	sensory	loss	(Carr	et	al.,	
2016;	Coelho	et	al.,	2017;	Maurer	et	al.,	2016).	Neurologic	symptoms	
and the pattern of progression of neurologic manifestations may vary 
according	to	mutation	type	(Cappellari	et	al.,	2011;	Carr	et	al.,	2016).	
Recognizing	hATTR	as	a	cause	of	polyneuropathy	may	be	challeng‐
ing because of its similarity to more common causes of neuropathy. 
Symptoms	that	may	help	to	distinguish	hATTR	from	other	causes	of	
neuropathy	 include	neuropathic	 pain	 (often	described	 as	 lightning	
pain),	autonomic	dysfunction,	absence	of	ataxia,	small	fiber	sensory	
loss	above	the	wrist,	and	weakness	in	the	upper	limbs,	and	are	more	
common	 in	 hATTR	 (Lozeron	 et	 al.,	 2018).	 Autonomic	 neuropathy	
can	manifest	as	orthostatic	hypotension	and/or	sexual	dysfunction	
but	may	not	be	reported	(Carr	et	al.,	2016;	Koike,	Nakamura,	et	al.,	
2018;	Lozeron	et	al.,	2018;	Maurer	et	al.,	2016;	Wixner,	Tornblom,	
Karling,	 Anan,	 &	 Lindberg,	 2018).	 Therefore,	 patients	 presenting	
with	progressive	length‐dependent	neuropathy	of	unknown	origin,	
particularly	those	with	concomitant	autonomic	dysfunction,	should	
be	 tested	 for	ATTR.	Additional	 symptoms	 include	progressive	car‐
diomyopathy and gastrointestinal disturbances. Progressive car‐
diomyopathy results in a rapid decline in cardiac functional capacity 
(Castano	et	al.,	2016;	Ruberg	et	al.,	2012).	Patients	may	experience	
rhythm	disturbances,	dyspnea,	syncope,	and	palpitations	(Maurer	et	
al.,	2016).	Gastrointestinal	disturbances	include	gastroparesis	lead‐
ing	 to	nausea	 and	 vomiting,	 alternating	diarrhea	 and	 constipation,	
and	unintentional	weight	loss	(Coelho,	Maurer,	&	Suhr,	2013;	Maurer	
et	al.,	2016;	Wixner	et	al.,	2018).
An	 early,	 potential	 red‐flag	manifestation	 of	ATTR	 amyloidosis	
is	bilateral	carpal	tunnel	syndrome	(Carr	et	al.,	2016;	Nakagawa	et	
al.,	2016).	Bilateral	carpal	tunnel	syndrome	in	combination	with	pro‐
gressive symmetric sensorimotor neuropathy and/or cardiomyopa‐
thy	should	raise	suspicion	of	ATTR	(Carr	et	al.,	2016;	Conceicao	et	
al.,	2016;	Nakagawa	et	al.,	2016;	Sperry	et	al.,	2018).
3.2 | Assessment and diagnosis of ATTR
In	 patients	with	 signs,	 symptoms,	 or	manifestations	 suggestive	 of	
amyloidosis,	diagnostic	and	genetic	testing	are	of	utmost	importance.	
Neurologic	and	cardiac	symptoms	can	be	evaluated	with	numerous	
tests	and	procedures,	including	tissue	biopsy,	Congo	red	staining	to	
confirm	the	presence	of	amyloid,	and	mass	spectrometry	or	immuno‐
histochemistry	to	confirm	the	type	of	amyloid	(Figure	1a,b)	(Benson	
et	 al.,	 2011;	 Carvalho,	 Rocha,	 &	 Lobato,	 2015;	 Coelho,	 Maurer,	 
et	al.,	2013;	Gilbertson	et	al.,	2015;	Linke,	Oos,	Wiegel,	&	Nathrath,	
2006;	Sperry	et	al.,	2018).	Genetic	testing	is	required	to	differentiate	
wtATTR	from	hATTR	and	to	allow	for	the	detection	of	specific	TTR 
gene	mutations,	which	may	help	predict	the	clinical	course	of	disease	
(Coelho,	Maurer,	et	al.,	2013).	In	patients	with	a	family	history,	it	may	
be appropriate to proceed directly to genetic testing.
Myocardial radiotracer uptake on bone scintigraphy is an 
alternative	 to	 tissue	 diagnosis	 for	 patients	 with	 cardiac	 ATTR	
(Gillmore	 et	 al.,	 2016).	 Myocardial	 uptake	 of	 bone	 scintigraphy	
agents	 (e.g.,	99mtechnetium	 [Tc]‐pyrophosphate	 scintigraphy	and	
99mTc‐3,3‐diphosphono‐1,2‐propanodicarboxylic	acid)	is	sensitive	
and	 specific	 for	 the	 diagnosis	 of	 TTR	 cardiac	 amyloid,	 if	 results	
of	screening	 tests	 for	 light	chain	amyloid	 (serum	and	urine	elec‐
trophoresis	with	immunofixation	and	serum	free	light	chains)	are	
negative	(Bokhari	et	al.,	2018;	Gertz	et	al.,	2015;	Gillmore	et	al.,	
2016;	Nativi‐Nicolau	&	Maurer,	2018).	The	use	of	bone	scintigra‐
phy is more sensitive than echocardiography in detecting early 
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cardiac	ATTR.	Patients	with	cardiac	amyloid	detected	via	scintig‐
raphy should also be evaluated for neuropathy because patients 
with	hATTR	often	have	a	mixed	phenotype.	This	will	ensure	ap‐
propriate treatment.
3.3 | Therapeutic landscape for ATTR
3.3.1 | Liver transplantation
Liver	 transplantation	 is	 a	 standard	 treatment	 option	 for	 hATTR	
because replacing the primary source of mutant TTR substantially 
reduces its production. The efficacy of liver transplantation has 
been demonstrated in studies showing improvement in sensory 
and	motor	impairment	(Okumura	et	al.,	2016),	as	well	as	improve‐
ment	 in	 long‐term	 overall	 survival	 (Yamashita	 et	 al.,	 2012).	 The	
10‐year	posttransplantation	 survival	 rate	exceeds	70%	 for	 some	
patients	 with	 hATTR	 (Suhr,	 Larsson,	 Ericzon,	 &	Wilczek,	 2016).	
Despite	reports	of	successful	outcomes	with	liver	transplantation,	
progression of peripheral and autonomic neuropathy and cardio‐
myopathy	have	occurred	following	liver	transplantation	(Banerjee	
et	al.,	2017).	Additionally,	numerous	factors,	such	as	genotype	and	
pretransplantation	(e.g.,	modified	body	mass	index	[mBMI])	char‐
acteristics,	 have	 been	 shown	 to	 affect	 posttransplantation	 sur‐
vival	(Banerjee	et	al.,	2017;	Suhr	et	al.,	2016).	The	10‐year	survival	
rate	 is	 as	 low	 as	 23%	 for	 patients	with	 Ser50Arg	 hATTR	 and	 as	
high	as	85%	for	patients	with	Val71Ala	hATTR	(Suhr	et	al.,	2016).	
In	multivariate	 analysis,	 the	 presence	 of	Val30Met	 hATTR	 is	 as‐
sociated	with	significantly	reduced	mortality	(Ericzon	et	al.,	2015).	
Additional	 factors	 to	consider	when	selecting	patients	 for	 trans‐
plantation	are	availability	of	donor	liver/graft,	patient	fitness,	the	
need	 for	 long‐term	 immunosuppression,	and	posttransplantation	
complications.
 Signs, symptoms, and manifestationsb
Neuropathy Progressive	symmetric	peripheral	sensorimotor	neuropathy	(plus	≥	1	
other	“red‐flag”	manifestation)	is	suggestive	of	hATTRa
Bilateral	carpal	
tunnel syndrome
Bilateral	carpal	tunnel	syndrome	(especially	if	family	history)a
Autonomic	
neuropathy
• Orthostatic hypotensiona
• Erectile dysfunctiona
•	 Recurrent	urinary	tract	infection	(due	to	urinary	retention)
•	 Sexual	dysfunction
• Sweating abnormalities
Cardiovascular 
manifestations
•	 Irregular	heartbeat	(atrial	fibrillation	most	common)a
•	 Conduction	blocks	(including	bundle	branch	blocks)a
•	 Congestive	heart	failure	(including	shortness	of	breath,	generalized	
fatigue,	and	peripheral	edema)
•	 Ventricular	wall	thickening	with	preserved	ejection	fraction	and	 
absence of left ventricular dilationa
• Cardiomyopathy
• Mild regurgitation
Gastrointestinal	
manifestations
•	 Nausea	and	vomiting
• Early satiety
• Chronic diarrheaa
• Severe constipationa
• Diarrhea/constipationa
• Unintentional weight lossa
Nephropathy •	 Albuminuriaa
•	 Mild	azotemiaa
• Protein in urine
• Renal failure
Ocular 
manifestations
• Dark floatersa
•	 Glaucoma
•	 Abnormal	blood	vessels	in	eye
• Pupillary abnormalities
Other •	 Lumbar	spinal	stenosisa
• Spontaneous distal biceps tendon rupturea
Abbreviations:	ATTR,	amyloid	transthyretin;	hATTR,	hereditary	amyloid	transthyretin	amyloidosis.
aRed‐flag	manifestations.	
bCentral nervous system symptoms can occur with certain TTR mutations but are not a common 
manifestation. 
TA B L E  1  Signs,	symptoms,	and	“red‐
flag”	manifestationsa	of	ATTR	amyloidosis	
(Castano	et	al.,	2016;	Coelho	et	al.,	2008;	
Conceicao	et	al.,	2016;	Donnelly	&	Hanna,	
2017;	Galat	et	al.,	2016;	Geller	et	al.,	2017;	
Gertz,	2018;	Ruberg	&	Berk,	2012;	Sperry	
et	al.,	2018)
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3.3.2 | Transthyretin stabilizers
In	hATTR,	mutations	are	 thought	 to	weaken	 interactions	between	
the	normally	 tetrameric	TTR,	 causing	dissociation	 into	monomeric	
TTR,	 a	 species	 prone	 to	 misfolding	 and	 aggregation	 (Figure	 2)	
(Bulawa	et	al.,	2012;	Saldano,	Zanotti,	Parisi,	&	Fernandez‐Alberti,	
2017).	The	rate‐limiting	step	in	fibril	formation	is	TTR	tetramer	dis‐
sociation	to	folded	dimers.	Therefore,	preventing	TTR	tetramer	dis‐
sociation is one approach to preventing amyloid fibril formation and 
is	the	mechanism	of	action	of	the	TTR	stabilizers	tafamidis	and	difl‐
unisal	(Bulawa	et	al.,	2012;	Sekijima,	Dendle,	&	Kelly,	2006).
Tafamidis
Tafamidis,	a	kinetic	TTR	stabilizer,	binds	to	the	unoccupied	thyroxine	
binding	sites	of	tetrameric	TTR,	preventing	the	amyloidogenic	cas‐
cade	(Bulawa	et	al.,	2012;	Pfizer	Ltd,	2016).	It	is	approved	in	Europe	
for	the	treatment	of	ATTR	amyloidosis	in	adults	with	stage	1	symp‐
tomatic	polyneuropathy	(Pfizer	Ltd,	2016)	(graded	on	a	scale	from	1	
F I G U R E  1  Diagnostic	workup	for	polyneuropathy	(a)	and	cardiomyopathy	(b)	when	ATTR	amyloidosis	is	suspected	(Carvalho	et	
al.,	2015;	Castano	et	al.,	2016;	Coelho	et	al.,	2008;	Conceicao	et	al.,	2016;	Donnelly	&	Hanna,	2017;	Galat	et	al.,	2016;	Geller,	Singh,	
Alexander,	Mirto,	&	Falk,	2017;	Gertz,	2017,	2018;	Gillmore	et	al.,	2016;	Nativi‐Nicolau	&	Maurer,	2018;	Ruberg	&	Berk,	2012;	Sperry	et	
al.,	2018).	99mTc,	technetium‐99m;	AL,	amyloid	light	chain;	ATTR,	amyloid	transthyretin;	CMR,	cardiac	magnetic	resonance	imaging;	DPD,	
3,3‐diphosphono‐1,2‐propanodicarboxylic	acid;	ECG,	electrocardiogram;	echo,	echocardiogram;	hATTR,	hereditary	amyloid	transthyretin;	
MRI,	magnetic	resonance	imaging;	PYP,	pyrophosphate;	TTR,	transthyretin;	wtATTR,	wild‐type	amyloid	transthyretin.	Panel	A:	a“Red‐flag”	
manifestations	include	progressive	symmetric	peripheral	sensorimotor	neuropathy	plus	≥	1	of	the	following:	bilateral	carpal	tunnel	syndrome	
(especially	family	history),	orthostatic	hypotension,	erectile	dysfunction,	irregular	heartbeat	(especially	atrial	fibrillation),	conduction	blocks	
(including	bundle	branch	blocks),	ventricular	wall	thickening	with	preserved	ejection	fraction	and	absence	of	left	ventricular	dilation,	chronic	
diarrhea,	severe	constipation,	diarrhea/constipation,	unintentional	weight	loss,	albuminuria,	mild	azotemia,	dark	floaters,	lumbar	spinal	
stenosis,	and/or	spontaneous	distal	biceps	tendon	rupture.	Modified	with	permission	from	Gertz	(2018)
(a)
(b)
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[lowest	disease	burden]	 to	3	 [greatest	disease	burden])	 (Coelho	et	
al.,	2017).	It	is	approved	in	several	other	countries	(e.g.,	Japan,	Brazil,	
Mexico),	but	it	is	not	approved	in	the	United	States	for	the	treatment	
of	polyneuropathy	of	ATTR	amyloidosis.
The efficacy and safety of tafamidis have been demonstrated in 
patients	with	early‐stage	hATTR	polyneuropathy	and	most	 recently	
in	patients	with	hATTR	cardiomyopathy;	however,	the	drug's	efficacy	
in	mid‐	to	late‐stage	hATTR	and	across	a	broad	range	of	hATTR	geno‐
types	is	mixed.	Two	studies	in	patients	with	early‐stage	hATTR	poly‐
neuropathy—Fx‐005	(clinicaltrials.gov	 identifier:	NCT00409175)	and	
Fx‐006	 (clinicaltrials.gov	 identifier:	 NCT00791492)—demonstrated	
less neurologic deterioration with tafamidis 20 mg once daily com‐
pared	with	placebo	but	did	not	reach	statistical	significance	(Coelho,	
Maia,	et	al.,	2013;	Coelho	et	al.,	2012).	The	efficacy	and	adverse	event	
profile observed in these studies led to the approval of tafamidis in the 
European	Union	in	2011	(Pfizer	Ltd,	2016).	Sustained	activity	and	tol‐
erability	of	tafamidis	for	up	to	6	years	have	been	reported	(clinicaltrials.
gov	 identifier:	NCT00925002)	 (Barroso	 et	 al.,	 2017);	 however,	 out‐
comes	are	mixed	for	patients	with	mid‐	to	late‐stage	Val30Met	hATTR	
and	patients	with	any‐stage	non‐Val30Met	hATTR.	Neuropathy	pro‐
gression	and	increasing	disability	in	patients	with	late‐stage	Val30Met	
hATTR	(Lozeron	et	al.,	2013)	and	worsening	in	neurologic	function	in	
patients	with	non‐Val30Met	hATTR	have	been	demonstrated	(Merlini	
et	al.,	2013).	 In	addition	 to	neuropathy	progression	 in	patients	with	
non‐Val30Met	 hATTR,	 Cortese	 et	 al.	 (2016)	 reported	worsening	 in	
autonomic function in patients with baseline dysautonomia and wors‐
ening in cardiac function in patients with baseline cardiac disease. 
Furthermore,	albeit	based	on	a	single	report,	Cortese	et	al	reported	
approximately	 one‐third	 of	 patients	without	 cardiac	 involvement	 at	
baseline developed cardiac disease during tafamidis treatment. In 
general,	tafamidis	was	well	tolerated.	The	mixed	outcomes	in	patients	
with	 mid‐	 and	 late‐stage	 Val30Met	 hATTR	 or	 with	 any‐stage	 non‐
Val30Met	hATTR	and	the	limited	impact	on	polyneuropathy	in	general	
underscore the need to identify patients who do not respond to tafa‐
midis so that other treatments might be considered.
Recently,	the	efficacy	and	safety	of	tafamidis	were	evaluated	
in	 the	 treatment	 of	 ATTR	 cardiomyopathy.	 A	 double‐blind,	 pla‐
cebo‐controlled,	phase	3	study	involving	patients	with	wtATTR	or	
hATTR	 compared	 the	 efficacy	 and	 safety	 of	 tafamidis	 20	mg	 or	
80	mg	once	daily	and	placebo	(ATTR‐ACT;	clinicaltrials.gov	 iden‐
tifier:	 NCT01994889)	 (Maurer	 et	 al.,	 2018).	 After	 30	months	 of	
follow‐up,	a	significant	reduction	in	all‐cause	mortality	and	cardio‐
vascular‐related	 hospitalization,	 assessed	 hierarchically,	 was	 ob‐
served	for	tafamidis	(20	and	80	mg	once	daily	pooled)	compared	
with	placebo.	Tafamidis	reduced	the	rate	of	all‐cause	mortality	by	
30%	and	cardiovascular‐related	hospitalizations	by	32%.	Although	
benefit	was	observed	with	tafamidis,	prespecified	subgroup	analy‐
sis	showed	that	in	patients	with	New	York	Heart	Association	class	
III	 disease,	 cardiovascular‐related	 hospitalizations	 were	 higher	
among patients receiving tafamidis than among those receiving 
placebo.	Additionally,	all‐cause	mortality	and	cardiovascular	hos‐
pitalization	did	not	 reach	 statistical	 significance	 in	 patients	with	
hATTR.	Patients	receiving	tafamidis	experienced	a	significant	re‐
duction	 in	 the	decline	of	 functional	capacity	 (assessed	by	 the	6‐
min	walk	 test)	 and	 quality	 of	 life	 (QOL;	 assessed	 by	 the	Kansas	
City	 Cardiomyopathy	 Questionnaire–Overall	 Summary	 score)	
than patients receiving placebo.
Findings	from	this	study	provided	data	for	the	approval	of	tafa‐
midis	meglumine	 (Vyndaqel,	Pfizer,	 Inc.)	and	 tafamidis	 (Vyndamax,	
Pfizer,	Inc.)	in	the	treatment	of	cardiomyopathy	of	wtATTR	or	hATTR	
in	adults	 to	reduce	cardiovascular	mortality	and	cardiovascular‐re‐
lated	hospitalization	(Pfizer,	2019).
Diflunisal
Diflunisal,	a	nonsteroidal	anti‐inflammatory	drug	(NSAID),	has	TTR‐
stabilizing	properties	and	has	been	used	off‐label	for	the	treatment	
of	hATTR.	In	a	randomized,	placebo‐controlled,	double‐blind,	inves‐
tigator‐initiated	 study	 (clinicaltrials.gov	 identifier:	 NCT00294671),	
the	 difference	 in	 Neuropathy	 Impairment	 Score	 +	 7	 neurophysi‐
ologic	 tests	 composite	 score	 (NIS	 +	 7)	 between	diflunisal	 250	mg	
twice daily and placebo at 2 years indicated decreased neuropathy 
progression	 (Berk	 et	 al.,	 2013).	 Additionally,	 physical	 and	 mental	
scores	on	the	36‐Item	Short‐Form	Health	Survey	indicated	improve‐
ment	in	QOL.
Despite	 the	 efficacy	 of	 diflunisal,	 adverse	 events	 associated	
with	 NSAIDs—specifically	 gastrointestinal,	 renal,	 cardiac,	 and	
blood‐related	events—are	a	concern	for	patients	with	hATTR	and	
may	preclude	use	of	diflunisal	in	specific	patients.	NSAID‐related	
adverse	 events,	 including	 acute	 renal	 failure	 (Azorin,	 Cabib,	 &	
Campistol,	2017),	deterioration	in	renal	function,	and	thrombocy‐
topenia	(Sekijima,	Tojo,	Morita,	Koyama,	&	Ikeda,	2015),	have	been	
shown	in	2	recent	studies	conducted	in	Spain	and	Japan.
F I G U R E  2   Mechanism of amyloid 
formation. aRate‐limiting	step	involves	
dissociation of tetrameric TTR to a pair of 
dimeric	TTRs,	which	rapidly	progresses	
to monomeric TTR. bMisfolded protein 
can	form	a	variety	of	toxic	intermediates,	
including	amyloid	fibrils	(shown	here);	
small oligomers; and amorphous 
aggregates.	TTR,	transthyretin.	Modified	
with	permission	from	Bulawa	et	al.	(2012)
TTR Structures
Associated with Pathologyb
AggregationProtein
misfolding
Rate-Limiting Stepa
Dissociation
Amyloid FibrilsMisfolded ProteinMonomerTetramer
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TA B L E  2  Main	properties	of	TTR	gene	knockdown	therapies	(Ackermann	et	al.,	2016;	Adams,	Gonzalez‐Duarte,	O'Riordan,	Yang,	Ueda,	
et	al.,	2018;	Akcea	Therapeutics,	Inc.,	2018a;	Alnylam	Netherlands	B.V.,	2018;	Alnylam	Pharmaceuticals	Inc.,	2018;	Ionis	USA	Ltd,	2018)
 Inotersen Patisiran
Indication Polyneuropathy	of	hATTR	in	adults	(United	States)
Stage	1	or	2	polyneuropathy	in	adults	with	hATTR	(European	Union)
Polyneuropathy	of	hATTR	in	adults	(United	States)
Stage	1	or	2	polyneuropathy	in	adults	with	hATTR	
(European	Union)
Therapeutic 
dose
284	mg 0.3 mg/kg
For	patients	weighing	≥100	kg,	adjust	dose	to	30	mg	
once every 3 weeks
Administration Once weekly Every 3 weeks
Route of 
administration
Subcutaneous Intravenous
Premedication Not	required •	 Intravenous	corticosteroid	(e.g.,	dexamethasone	
10	mg	or	equivalent)
•	 Oral	acetaminophen	(500	mg)
•	 Intravenous	H1	blocker	(e.g.,	diphenhydramine	
50	mg	or	equivalent)
•	 Intravenous	H2	blocker	(e.g.,	ranitidine	50	mg	or	
equivalent)
Precautions Vitamin	A	supplementation	at	a	dose	consistent	with	the	recommended	daily	
allowance is warranted
Vitamin	A	supplementation	at	a	dose	consistent	with	
the recommended daily allowance is warranted
Mechanism of 
action
Antisense	oligonucleotide	inhibitor	that	degrades	mRNA	via	nuclear	RNaseH1
• Inhibits human TTR production by selectively binding to TTR	mRNA
•	 Degrades	both	mutant	and	wild‐type	(normal)	TTR	mRNA
Small	interfering	RNA	that	degrades	TTR	via	cytoplas‐
mic	RNA‐induced	silencing	complex
• Inhibits human TTR production by selectively bind‐
ing to TTR	mRNA
•	 Degrades	both	mutant	and	wild‐type	(normal)	TTR 
mRNA
TTR reduction 79%	(median	nadir	[predose]	weeks	13–65) 81%	(median	reduction	[postdose]	over	18	months)
Safety 
monitoringa
• Thrombocytopenia
o	 Monitor	platelet	count	weekly	during	treatment	if	values	are	≥100	×	109/L
o	 Stop	treatment	if	platelet	count	is	≥75	to	˂100	×	109/L;	monitor	platelet	
count	weekly	until	values	resume	to	˃100	×	109/L
o	 Stop	treatment	if	platelet	count	is	≥50	to	˂75	×	109/L;	monitor	platelet	
count	twice	weekly	until	3	successive	values	resume	to	 7˃5	×	109/L;	once	
values	resume,	monitor	weekly
o	 Stop	treatment	if	platelet	count	is	≥25	to	˂50	×	109/L;	monitor	platelet	
count	twice	weekly	until	3	successive	values	resume	to	 7˃5	×	109/L;	once	
values	resume,	monitor	weekly.	More	frequent	monitoring	is	warranted	if	
risk	factors	for	bleeding	are	present;	corticosteroids	(glucocorticoids)	are	
strongly	recommended,	and	discontinuation	of	antiplatelets/anticoagu‐
lants should be considered
o	 Stop	treatment	if	platelet	count	is	˂25	×	109/L;	monitor	platelet	count	
daily	until	2	successive	values	resume	to	˃25	×	109/L;	once	values	
resume,	monitor	twice	weekly	until	values	resume	to	˃75	×	109/L;	once	
values	resume,	monitor	weekly.	More	frequent	monitoring	is	warranted	
if	risk	factors	for	bleeding	are	present;	corticosteroids	(glucocorticoids)	
are	strongly	recommended,	and	discontinuation	of	antiplatelets/anti‐
coagulants should be considered
•	 Glomerulonephritis/renal	function	decline
o	 Monitor	serum	creatinine,	eGFR,	urinalysis,	and	UPCR	every	2	weeks	 
during treatment
o	 Withhold	inotersen	if	UPCR	is	≥1,000	mg/g,	or	if	eGFR	is	˂45	ml/min/1.73	
m2;	dosing	can	resume	once	eGFR	increases	to	≥45	ml/min/1.73	m2,	UPCR	
decreases	to	˂1,000	mg/g,	or	the	underlying	cause	of	the	decline	in	renal	
function is corrected
o	 If	UPCR	is	≥2,000	mg/g,	the	presence	of	acute	glomerulonephritis	should	
be investigated; discontinue inotersen if acute glomerulonephritis is 
confirmed
•	 Liver	function
o	 Monitor	ALT,	AST,	and	total	bilirubin	every	4	months
Not	required
Abbreviations:	ALT,	alanine	aminotransferase;	AST,	aspartate	aminotransferase;	eGFR,	estimated	glomerular	filtration	rate;	hATTR,	hereditary	 
amyloid	transthyretin	amyloidosis;	TTR,	transthyretin;	UPCR,	urine	protein‐to‐creatinine	ratio.
aBased	on	US	prescribing	information.	The	reader	should	refer	to	country‐specific	monitoring	and	treatment	recommendations.	
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Collectively,	 tafamidis	 and	 diflunisal	 have	 demonstrated	 bene‐
fit	 in	 the	 treatment	of	hATTR,	but	 their	benefit	may	be	 limited	by	
potential variable efficacy in specific patient populations and by an 
increased	potential	for	adverse	events	(diflunisal).
3.3.3 | Transthyretin protein knockdown (reduction) 
agents (gene silencing)
Inotersen	 and	 patisiran	 recently	 received	 marketing	 authorization	
for the treatment of neuropathy. These agents substantially reduce 
TTR protein levels by degrading TTR	mRNA,	specifically	degradation	
of	mRNA	via	nuclear	RNaseH1	with	inotersen	or	cytoplasmic	RNA‐
induced	 silencing	 complex	with	 patisiran	 (Ackermann	 et	 al.,	 2016;	
Adams,	Gonzalez‐Duarte,	O'Riordan,	Yang,	Ueda,	et	al.,	2018).	Both	
mechanisms of action differ from liver transplantation in that both 
mutated	 and	 wild‐type	 TTR	 production	 are	 targeted.	 Reductions	
in	mutated	and	wild‐type	TTR	delay	or	halt	progression	of	existing	
neurologic	manifestations,	and	reductions	in	wild‐type	TTR	may	pre‐
vent	 the	 development	 of	 new	manifestations.	 Both	 inotersen	 and	
patisiran	 have	 demonstrated	 efficacy	 in	 patients	 with	 early‐	 and	
late‐stage	neurologic	disease;	however,	they	differ	 in	terms	of	for‐
mulation,	dosing,	premedication	requirements,	and	safety	monitor‐
ing	(Table	2).
Inotersen
Inotersen,	a	once‐weekly	subcutaneously	administered	antisense	ol‐
igonucleotide	therapy,	is	approved	in	the	United	States	for	the	treat‐
ment	of	 the	polyneuropathy	of	hATTR,	and	 in	Europe	and	Canada	
for the treatment of stage 1 or 2 polyneuropathy in adult patients 
with	hATTR	(Akcea	Therapeutics,	Inc.,	2018a,	2018b;	Ionis	USA	Ltd,	
2018).	Initial	preclinical	and	clinical	studies	demonstrated	sustained	
reductions in TTR	mRNA	and	protein	levels	(Ackermann	et	al.,	2016),	
and	on	the	basis	of	these	studies	the	phase	3,	randomized,	double‐
blind,	placebo‐controlled	study	NEURO‐TTR	was	 initiated	(clinical‐
trials.gov	identifier:	NCT01737398)	(Benson	et	al.,	2018).
In	NEURO‐TTR,	173	patients	with	hATTR	polyneuropathy	were	
randomly assigned 2:1 to receive subcutaneous inotersen 300 mg 
once	weekly	 (n = 113; n	=	112	 treated)	or	placebo	 (n	=	60)	 strati‐
fied	by	mutation	status,	disease	stage,	and	prior	stabilizer	treatment	
(Benson	 et	 al.,	 2018).	 Baseline	 demographic	 and	 disease	 charac‐
teristics were generally balanced across both treatment groups; 
however,	 patients	 receiving	 inotersen	had	a	 longer	mean	duration	
of	 hATTR	 polyneuropathy	 from	 diagnosis	 compared	with	 patients	
receiving	placebo	(mean,	42	vs.	39	months);	this	was	particularly	ev‐
ident	among	patients	with	stage	2	hATTR	(mean,	41	vs.	25	months)	
(Benson	et	al.,	2018;	Gertz	et	al.,	2018).	Additionally,	a	greater	pro‐
portion of patients receiving inotersen than placebo had cardiomy‐
opathy	(67%	vs.	55%)	and	had	a	 longer	duration	from	the	onset	of	
cardiomyopathy	symptoms	(mean,	48	vs.	34	months)	(Benson	et	al.,	
2018;	Gertz	et	al.,	2018).
In	NEURO‐TTR,	patients	treated	with	inotersen	showed	substan‐
tial	reductions	in	TTR	levels	that	were	sustained	over	time	(Benson	 
et	 al.,	 2018;	 Dyck	 et	 al.,	 2018).	 Inotersen	 treatment	 resulted	 in	 a	
median	TTR	 reduction	 from	baseline	 (measured	predose)	of	75%–
79%	between	months	3	and	15	(Dyck	et	al.,	2018).	Compared	with	
placebo,	patients	receiving	inotersen	experienced	a	statistically	sig‐
nificant	 improvement	 in	modified	NIS	+	7	 (mNIS	+	7)	 and	Norfolk	
Quality	 of	 Life–Diabetic	 Neuropathy	 questionnaire	 total	 score	
(Norfolk	QOL‐DN)	(co‐primary	end	points),	as	early	as	8	months	for	
mNIS	+	7	(p	˂	.001)	and	Norfolk	QOL‐DN	(p	=	.03),	with	effects	sus‐
tained	at	15	months	(both	p	˂	.001)	(Benson	et	al.,	2018).	Similar	ef‐
fects	were	observed	for	both	mNIS	+	7	and	Norfolk	QOL‐DN	across	
all	patient	subgroups,	based	on	study	stratification	factors,	indicating	
clinical benefit across a broad spectrum of important disease char‐
acteristics	(Benson	et	al.,	2018).	Improvement	in	neuropathy‐related	
QOL,	as	indicated	by	the	reduction	in	Norfolk	QOL‐DN	scores,	was	
corroborated by significant improvement in the physical component 
summary	score	of	36‐Item	Short‐Form	Health	Survey	at	15	months	
for	inotersen	compared	with	placebo	(Benson	et	al.,	2018).
Significant	improvements	from	baseline	to	15	months	in	favor	of	
inotersen were observed in the subset of patients with both poly‐
neuropathy	 and	 cardiomyopathy	 for	 the	 co‐primary	 end	 points,	
mNIS	+	7	 (p	<	 .001)	and	Norfolk	QOL‐DN	(p	=	 .04)	 (Benson	et	al.,	
2018).
Common	 adverse	 events,	 defined	 as	 adverse	 events	 occurring	
in	˃10%	and	twice	as	frequently	in	patients	receiving	inotersen	than	
placebo,	included	nausea,	pyrexia,	chills,	vomiting,	anemia,	thrombo‐
cytopenia,	and	lowered	platelet	counts	(Benson	et	al.,	2018).	The	rate	
of	injection‐site	reactions	was	1.1%	of	all	injections	in	patients	who	
received	inotersen.	Most	(97%)	were	mild	in	severity,	and	no	patient	
discontinued	because	of	injection‐site	reactions.	Five	(4.5%)	deaths	
occurred,	and	all	were	in	inotersen‐treated	patients;	however,	all	but	
one	were	because	of	disease	progression	or	underlying	disease.	A	
single death occurred because of fatal intracranial hemorrhage as‐
sociated with serious thrombocytopenia in a patient whose platelets 
had	not	been	monitored,	as	the	event	occurred	before	routine	mon‐
itoring was implemented; similar events did not occur after monitor‐
ing	was	implemented	(Benson	et	al.,	2018).	Safety	concerns	include	
thrombocytopenia	and	glomerulonephritis,	which	were	monitorable	
and	manageable	following	implementation	of	more	frequent	plate‐
let	(weekly)	and	renal	(every	2–3	weeks)	monitoring	in	the	NEURO‐
TTR	study	 (Benson	et	al.,	2018).	 In	order	 to	manage	and	minimize	
the	potential	 risk	of	serious	bleeding	and	glomerulonephritis,	 inot‐
ersen is available through a restricted distribution program under a 
Risk	Evaluation	 and	Mitigation	 Strategy	 (Akcea	Therapeutics,	 Inc.,	
2018a).	Enhanced	monitoring	for	thrombocytopenia,	glomerulone‐
phritis/renal	function,	and	liver	function	is	recommended	(Table	2)	
(Akcea	Therapeutics,	Inc.,	2018a;	Ionis	USA	Ltd,	2018).
The sustained benefit and tolerability of inotersen were 
demonstrated	 in	 the	 ongoing	 phase	 3	 open‐label	 extension	 study	
of	 NEURO‐TTR	 (clinicaltrials.gov	 identifier:	 NCT02175004)	
(Brannagan	et	al.,	2018).	In	NEURO‐TTR,	81%	of	patients	completed	
the	15‐month	treatment	period	and	˃95%	enrolled	in	the	open‐label	
extension	 study	 (Benson	 et	 al.,	 2018).	 Extended	dosing	with	 inot‐
ersen,	reaching	5.2	years	for	the	longest	time	any	patient	received	
treatment,	 demonstrated	 continued	 slowing	 or	 improvement	 of	
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neuropathy	progression	after	2	years	of	follow‐up	(Brannagan	et	al.,	
2018).	Additionally,	initiation	of	inotersen	in	the	extension	study	in	
patients who previously received placebo resulted in disease stabi‐
lization	(Brannagan	et	al.,	2018).	Although	patients	who	previously	
received	placebo	experienced	 rapid	benefit,	 the	delay	 in	 receiving	
inotersen	 resulted	 in	 less	 improvement	 in	 mNIS	 +	 7	 and	 Norfolk	
QOL‐DN	than	 those	of	patients	who	started	 inotersen	earlier	and	
remained	on	inotersen,	suggesting	that	treatment	with	inotersen	al‐
tered	the	natural	history	of	the	disease.	Importantly,	no	new	safety	
concerns	were	 identified,	and	 there	was	no	evidence	of	 increased	
risk for grade 4 thrombocytopenia or glomerulonephritis with in‐
creased	duration	of	inotersen	exposure.	Taken	together,	these	data	
confirm the urgency to treat patients as early as possible.
Patisiran
Patisiran,	 a	 triweekly	 intravenously	 administered	 TTR‐directed,	
double‐stranded,	 small	 interfering	RNA,	 is	approved	 in	 the	United	
States	for	the	treatment	of	the	polyneuropathy	of	hATTR	in	adults	
(Alnylam	 Pharmaceuticals	 Inc.,	 2018)	 and	 in	 Europe	 for	 the	 treat‐
ment	of	hATTR	in	adults	with	stage	1	or	2	polyneuropathy	(Alnylam	
Netherlands	B.V.,	2018).	It	is	formulated	as	a	lipid	complex	to	ensure	
adequate	 targeting	 to	 the	 liver	 (Table	2)	 (Alnylam	Pharmaceuticals	
Inc.,	 2018;	 Suhr	 et	 al.,	 2015).	 There	 is	 the	 potential	 for	 infusion‐
related	 reactions	 to	 occur	 because	 of	 the	 lipid‐based	 delivery	 of	
patisiran;	therefore,	patients	receive	a	premedication	regimen	con‐
sisting	of	an	intravenous	corticosteroid	(i.e.,	dexamethasone	10	mg	
or	equivalent),	H1	blocker,	and	H2	blocker,	as	well	as	oral	acetami‐
nophen	(Alnylam	Pharmaceuticals	Inc.,	2018;	Suhr	et	al.,	2015).
The	phase	3,	 randomized,	double‐blind,	placebo‐controlled	study	
APOLLO	 (clinicaltrials.gov	 identifier:	 NCT01960348)	 evaluated	 the	
efficacy	 and	 safety	 of	 patisiran	 compared	 with	 placebo	 (Adams,	
Gonzalez‐Duarte,	O'Riordan,	Yang,	Ueda,	et	al.,	2018).	A	total	of	225	
patients	with	hATTR	polyneuropathy	were	randomly	assigned	2:1	to	
patisiran	0.3	mg/kg	once	every	3	weeks	(n	=	148)	or	placebo	(n	=	77)	
and	were	stratified	by	NIS,	disease	onset/genotype,	and	previous	stabi‐
lizer	use.	Baseline	demographics	and	disease	characteristics	were	gen‐
erally	balanced	between	treatment	groups,	although	a	slightly	higher	
proportion of patients in the overall population had disease stage 2 
(53%)	than	disease	stage	1	(46%).	Additionally,	a	greater	proportion	of	
patients receiving patisiran had cardiomyopathy compared with pa‐
tients	receiving	placebo	(61%	vs.	47%).	Patisiran	treatment	resulted	in	a	
median	TTR	reduction	from	baseline	(measured	postdose)	of	81%	over	
18	months	of	 treatment	 (Adams,	Gonzalez‐Duarte,	O'Riordan,	Yang,	
Ueda,	et	al.,	2018).
In	patients	receiving	patisiran,	a	statistically	significant	improve‐
ment	 in	mNIS	+	7	 (primary	end	point)	was	 achieved	at	18	months	
(p	 ˂	 .001)	 compared	 with	 placebo,	 with	 effects	 seen	 as	 early	 as	
9	months	 (Adams,	Gonzalez‐Duarte,	O'Riordan,	Yang,	Ueda,	 et	 al.,	
2018).	A	 similar	 effect	was	 observed	 for	mNIS	+	 7	 across	 all	 sub‐
groups based on study stratification factors. Significant improve‐
ment	in	neuropathy‐related	QOL,	as	indicated	by	Norfolk	QOL‐DN	
(secondary	 end	point),	was	 also	observed	 at	18	months	 (p	 ˂	 .001)	
with	 patisiran	 compared	 with	 placebo	 (Adams,	 Gonzalez‐Duarte,	
O'Riordan,	Yang,	Ueda,	et	al.,	2018).	Similar	 to	mNIS	+	7,	a	benefit	
in	 favor	 of	 patisiran	was	 observed	 for	Norfolk	QOL‐DN	 across	 all	
subgroups,	indicating	a	broad	clinical	benefit.	In	addition	to	improve‐
ment	 in	neuropathy	and	QOL,	 improvement	from	baseline	 in	favor	
of	patisiran	was	observed	at	18	months	for	gait	speed	(measured	by	
10‐m	walk	 test),	 nutritional	 status	 (measured	by	mBMI),	 and	auto‐
nomic	 symptoms	 (measured	 by	 Composite	 Autonomic	 Symptom	
Score	31)	 (Adams,	Gonzalez‐Duarte,	O'Riordan,	Yang,	Ueda,	 et	 al.,	
2018).	In	the	subset	of	patients	with	cardiomyopathy,	patisiran	was	
associated	 with	 significant	 improvements	 for	 the	 exploratory	 end	
points,	mean	 left	ventricular	wall	 thickness	 (p	=	 .02)	and	 longitudi‐
nal	 strain	 (p	 =	 .02),	 compared	with	 placebo	 at	 18	months	 (Adams,	
Gonzalez‐Duarte,	O'Riordan,	Yang,	Ueda,	et	al.,	2018).
In	 addition	 to	Norfolk	QOL‐DN,	QOL	was	 also	 assessed	 using	
Rasch‐built	 Overall	 Disability	 Scale	 (R‐ODS)—a	 measure	 of	 pa‐
tient‐perceived	 activity	 and	 social	 participation	 limitations—and	
EuroQOL‐5	dimension‐5	 level	 (EQ‐5D‐5L)	 and	EuroQOL‐visual	 an‐
alog	 scale	 (EQ‐VAS),	 two	 measures	 of	 patient‐perceived	 overall	
health	 status	 (van	Nes	 et	 al.,	 2011;	 van	Reenan	&	 Jannsen,	 2015;	
Regnault	et	al.,	2017).	Although	R‐ODS	was	originally	developed	for	
patients	 with	 other	 neuropathies	 (e.g.,	 Guillain–Barré	 syndrome),	
it	 has	 purported	 applicability	 to	 patients	 with	 hATTR	 (Regnault	 
et	al.,	2017);	 significant	differences	 in	R‐ODS	were	observed	with	
patisiran	 compared	with	placebo	at	18	months	 (Adams,	Gonzalez‐
Duarte,	O'Riordan,	Yang,	Ueda,	et	al.,	2018).	Additionally,	significant	
differences	in	EQ‐5D‐5L	and	EQ‐VAS	were	observed	with	patisiran	
compared	 with	 placebo	 at	 18	 months	 (Adams,	 Gonzalez‐Duarte,	
O'Riordan,	Yang,	Yamashita,	et	al.	2018).
Common	adverse	events	 that	occurred	more	 frequently	 in	pa‐
tients	 receiving	 patisiran	 included	 peripheral	 edema,	 upper	 re‐
spiratory	 tract	 infections,	 and	 infusion‐related	 reactions	 (Adams,	
Gonzalez‐Duarte,	 O'Riordan,	 Yang,	 Ueda,	 et	 al.,	 2018;	 Alnylam	
Pharmaceuticals	 Inc.,	 2018).	 Infusion‐related	 reaction	 symptoms	
included	 back	 pain,	 flushing,	 nausea,	 abdominal	 pain,	 headache,	
arthralgia,	 and	 dyspnea.	 Seven	 (5%)	 patients	 experienced	 an	 infu‐
sion‐related	 reaction	 that	 led	 to	 treatment	 interruption.	 A	 similar	
proportion of severe and serious adverse events occurred in pa‐
tients	receiving	patisiran	and	placebo,	with	approximately	one‐third	
of	patients	experiencing	either	type	of	adverse	event.	Notably,	more	
patients	receiving	patisiran	than	placebo	experienced	a	serious	ad‐
verse	event	of	complete	atrioventricular	block.	Seven	(5%)	deaths	(all	
cardiac‐related)	occurred	in	patients	receiving	patisiran,	and	six	(8%)	
occurred	in	patients	receiving	placebo	(none	cardiac‐related).
The	sustained	activity	of	patisiran	was	observed	with	extended	
dosing	in	an	ongoing	global	open‐label	extension	study	(clinicaltrials.
gov	 identifier:	NCT02510261)	 (González‐Duarte	 et	 al.,	 2018;	 Suhr	
et	al.,	2018).	In	APOLLO,	86%	of	patients	completed	the	18‐month	
treatment	period,	and	˃95%	of	patients	were	eligible	for	participa‐
tion	 in	 the	 open‐label	 extension	 study	 (Adams,	 Gonzalez‐Duarte,	
O'Riordan,	Yang,	Ueda,	et	al.,	2018).	Treatment	with	patisiran	for	up	
to 29 months in patients who continued to receive patisiran in the 
extension	study	demonstrated	disease	stabilization,	as	evidenced	by	
mNIS	+	7	 (González‐Duarte	et	al.,	2018).	Disease	stabilization	was	
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also observed with patisiran in patients who previously received pla‐
cebo	(González‐Duarte	et	al.,	2018).	No	new	safety	concerns	were	
identified	in	the	extension	study	(González‐Duarte	et	al.,	2018).
3.4 | Emerging/investigational therapies
Several investigational therapies are being evaluated for the treat‐
ment	of	hATTR	amyloidosis.	These	 therapies	 target	 specific	 aspects	
of	 the	amyloidogenic	cascade	and,	 in	 some	cases,	may	offer	advan‐
tages	over	existing	agents.	Several	agents	that	stabilize	TTR	are	being	
investigated,	 including	 epigallocatechin‐3‐gallate	 (EGCG),	 AG‐10,	
and	CHF5074.	EGCG,	a	catechin	 in	green	tea,	has	demonstrated	in‐
creased	stabilization	of	TTR	tetramers	and	a	reduction	in	TTR	deposi‐
tion	(Ferreira,	Saraiva,	&	Almeida,	2012).	In	a	mouse	model	of	hATTR	
amyloidosis	 with	 peripheral	 nervous	 system	 involvement,	 EGCG	
100 mg kg−1 day−1	 for	 6	weeks	 produced	 a	 significant	 reduction	 in	
TTR	deposition	in	dorsal	root	ganglia	and	sciatic	nerve	(Ferreira	et	al.,	
2012).	AG‐10,	a	kinetic	stabilizer,	binds	with	high	affinity	and	nega‐
tive	cooperativity	 to	TTR	 (Penchala	et	al.,	2013).	 In	preclinical	 stud‐
ies,	AG‐10	stabilizes	 tetramers	composed	of	wild‐type	and	mutated	
TTR	 equally	well,	whereas	 tafamidis	 showed	 greater	 stabilization	 of	 
wild‐type	 than	 mutated	 TTR	 (Penchala	 et	 al.,	 2013).	 CHF5074,	 an	
NSAID	derivative	without	cyclooxygenase	inhibitory	properties,	is	an‐
other	molecule	that	has	demonstrated	stabilization	of	wild‐type	and	
mutant	TTR	tetramers	(Mu	et	al.,	2015).	The	absence	of	cyclooxyge‐
nase	inhibitory	activity	offers	an	advantage	over	other	NSAID‐based	
TTR	stabilizers	in	that	it	may	prevent	unwanted	adverse	effects	asso‐
ciated	with	NSAIDs.	Additional	testing	is	needed	to	confirm	whether	
that	 is	 the	 case	 for	 CHF5074.	 Monoclonal	 antibodies	 directed	 at	
misfolded TTR are another therapeutic strategy being investigated 
for	 ATTR	 amyloidosis.	 Preclinical	 activity	 demonstrated	 the	 ability	
of	monoclonal	antibodies	to	prevent	amyloid	fibril	 formation	 (Higaki	
et	 al.,	 2016).	 Additionally,	 antibody‐dependent	 phagocytic	 uptake	
of	misfolded	TTR	was	 observed	 (Higaki	 et	 al.,	 2016).	 PRX004	 is	 an	
investigational	 antibody	 being	 evaluated	 in	 a	 phase	 1,	 open‐label,	
dose‐escalation	study	(clinicaltrials.gov	identifier:	NCT03336580)	(US	
National	Library	of	Medicine,	2018b).	Lastly,	second‐generation	TTR 
gene	knockdown	agents	 are	also	emerging.	AKCEA‐TTR‐LRx	 (Akcea	
Therapeutics,	 Inc.,	 2019),	 a	 subcutaneous	 antisense	 oligonucleotide	
with	 improved	hepatic	 targeting	with	 the	potential	 for	 less	 frequent	
and	lower	doses	of	drug,	is	in	phase	3	planning,	and	vutrisiran	(ALN‐
TTRsc02)	 (US	National	Library	of	Medicine,	2018a),	a	subcutaneous	
RNA	 interference	 therapeutic	 with	 the	 potential	 for	 less	 frequent	
doses	of	drug,	will	be	evaluated	in	the	phase	3	HELIOS‐A	study	(clini‐
caltrials.gov	identifier:	NCT03759379).
4  | CONCLUSIONS
Until	recently,	there	have	been	few	treatment	options	for	patients	
with	hATTR.	Recent	results	of	clinical	studies	for	tafamidis,	inotersen,	
and patisiran represent a significant advance in the field of amyloi‐
dosis.	The	 results	of	 the	 tafamidis	ATTR‐ACT	study	demonstrated	
significant	reductions	in	death	and	cardiovascular	hospitalization	for	
patients	with	ATTR	 cardiomyopathy,	 supporting	 the	 role	 of	 stabi‐
lizer	therapy	in	cardiac	patients,	especially	those	with	wtATTR.	The	
unique	mechanisms	of	action	of	 inotersen	and	patisiran	overcome	
many	 limitations	 of	 previous	 therapies	 for	 patients	 with	 hATTR.	
Both	agents	are	efficacious	in	patients	with	early‐	and	late‐stage	dis‐
ease	and	 improve,	halt,	 or	 slow	neuropathy	progression;	however,	
differences	in	formulation,	dosing,	requirements	for	premedications,	
and safety monitoring have important implications for patients and 
for	selecting	therapies.	Importantly,	direct	comparison	of	inotersen	
and	patisiran	 is	 not	 possible	 given	differences	 in	 the	NEURO‐TTR	
and	 APOLLO	 study	 designs,	 end	 points,	 and	 patient	 populations.	
Similarly,	direct	comparison	of	inotersen	and	patisiran	with	tafamidis	
for patients with cardiac disease is not possible given differences 
in	the	NEURO‐TTR,	APOLLO,	and	ATTR‐ACT	studies.	Additional	re‐
search is necessary to determine the optimal treatment for a given 
patient	with	ATTR.	It	is	possible	that	gene	silencing	therapy	in	com‐
bination	with	TTR‐stabilizing	therapy	or	an	agent	that	removes	fibril	
deposition	may	be	beneficial.	As	additional	evidence	for	current	and	
emerging	therapies	expands,	the	outlook	for	patients	with	ATTR	is	
becoming	more	promising,	offering	much‐needed	hope	for	a	debili‐
tating	and	life‐threatening	disease.
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